Consolidation, Price, and Health Spending in the US
Mergers between health systems have increased prices but have not shown consistent improvements in quality of care. However, these [...]
Unsubstantiated Drug-Price Hikes Identified by ICER
An ICER report examining the top ten drugs with 2020 price hikes found that a staggering seven out of ten [...]
Webinar: Biden, Congress, and Drug Prices
Drug pricing is being targeted by both the Biden administration and congress, according to a webinar now available on Research [...]
Ensuring that Insurance Benefits Members
A staggering 49% of patients with commercial insurance are still paying the full list price for medicine, even in cases [...]
75% of Insured Americans Worry About Medical Bills – Women Disproportionately Impacted
According to the recent MITRE Insurance Survey, 75% of insured Americans are worried about financial issues due to medical bills. [...]
ICER’s First Scorecard Finds Lack of Transparency of Drug Coverage Policies
The Institute for Clinical and Economic Review (ICER) reviewed barriers to fair access to fairly priced drugs, but found difficulties [...]
Value-based Pricing Programs Given Renewed Focus by Pfizer and Takeda
Value-based pricing and reimbursement models are not common in the United States, but this may change after recent programs by [...]
Role of Pharmacy Benefit Managers Under Congressional Scrutiny
The role of pharmacy benefit managers (PBM) on patient out of pocket prices was examined by a US congressional hearing [...]
Impacts of the Build Back Better Act on the Healthcare Industry
With the Build Back Better Act inching through the legislature, uncertainty is building regarding its effects on the healthcare industry. [...]
Avoiding Medical Bankruptcy with Quizzify Prevent Consent Clause
Half of all Americans have outstanding medical debt, and the same number cannot afford a medical emergency. Bills for emergency [...]
Upcoming ICER Webinar Will Discuss Barriers to Fair Access
On December 3rd (12 PM), the Institute for Clinical and Economic Review will host a public webinar detailing the findings [...]
Insurance Design Harms Patient Health with Barriers to Access
Patient health is harmed by barriers to access caused by Insurance design, according to The Pharmaceutical Research and Manufacturers of [...]
JAMA Network Open Article Highlights the Plight of the Uninsured as Drug Costs Soar
A recent article published in JAMA Network Open highlights one major healthcare spending trend: the uninsured. An increase in concentration [...]
Xcenda HEOR Experts Discuss ICER’s UPI Assessments
Xcenda’s Tasmina Hydery and Anne Loos shared their thoughts on the methodologies used by the Institute for Clinical and Economic [...]
[JAMA Article] New Oncology Drugs Command High Price Tags Despite Lack of Improved Survival
In an article published in JAMA Internal Medicine, researchers assessed the costs of 44 new oncology drugs. Surprisingly, they found [...]
ICER Releases Final Evidence Report for Hypertrophic Cardiomyopathy Drug
The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report for mavacamten, produced by MyoKardia and [...]
Amgen’s Patent Thicket Strategy Yields Billions in Drug Sales for TNF Inhibitor Enbrel
Amgen has employed a powerful strategy to maintain its monopoly on Enbrel, a drug that targets tumor necrosis factor (TNF) [...]
ICER Publishes Annual Hit List of 10 Drugs With Unsupported Price Hikes
The Institute for Clinical and Economic Review (ICER) has released its most recent report on Unsupported Price Increases (UPIs) for 2020. [...]
RWE Expert and Economist Details Future Global Market Access and Pricing Trends
Economist Ulf Staginnus shared his thoughts on future trends for market access and drug pricing in a recent discussion with [...]
Will Mark Cuban’s PBM Deliver on Pricing Promises?
Mark Cuban’s new pharmacy benefit manager (PBM) venture and employer-run EmsanaRx are two of the latest players to enter the [...]
CEVR Leaders Publish NEJM Article on Determining Value Using Cost-Effectiveness Analyses
Peter Neumann, Sc.D., Joshua Cohen, Ph.D., and Daniel Ollendorf, Ph.D. of the Center for the Evaluation of Value and Risk [...]
ICER Releases Evidence Report on Mavacamten for Hypertrophic Cardiomyopathy Ahead of FDA Approval
The Institute for Clinical and Economic Review (ICER) has released its evidence report for mavacamten, used to treat hypertrophic cardiomyopathy [...]
TransUnion Reports Widespread Delay of Healthcare as Coverage Gaps Increase and COVID-19 Uncertainty Continues
According to TransUnion, approximately 35% of patients with medical debt have put off healthcare in the past year. Key factors [...]
CEVR Director Publishes Article on Improving Data Dashboards for Drug Value Assessments
Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center Peter Neumann [...]
Pelosi’s Politicking Leads to Drug Pricing Deal
After 15 years, Democrats have managed to advance drug pricing legislation. House Speaker Nancy Pelosi unexpectedly opposed Medicare negotiation in [...]